UnknownPhase 3NCT01656980

Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shandong Lanjin Pharmaceuticals Co.,Ltd
Principal Investigator
Yan H Sun, M.D., MD, PhD
Beijing Tiantan Hospital
Intervention
Carmustine(drug)
Enrollment
236 enrolled
Eligibility
18-70 years · All sexes
Timeline
20122014

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01656980 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials